Innate and adaptive immunity and the pathophysiology of psoriasis

Journal of the American Academy of Dermatology

Volumn 54, Issue 3 SUPPL. 2, 2006, Pages

  Gaspari, Anthony A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTIMALARIAL AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHEMOKINE; CYCLOSPORIN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENILEUKIN DIFTITOX; EFALIZUMAB; ETANERCEPT; GROWTH FACTOR; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 4; LITHIUM; METHOTREXATE; METHOXSALEN; OKT 4; PSORALEN; RETINOID DERIVATIVE; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TACROLIMUS; TIOGUANINE; TOLL LIKE RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE MODEL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TARGETING; GENETIC DISORDER; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOTHERAPY; INFLAMMATION; INNATE IMMUNITY; NATURAL KILLER T CELL; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PUVA; REVIEW; T LYMPHOCYTE;

EID: 32644438521     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2005.10.057     Document Type: Article

References (96)

1. G.G. Krueger, P.R. Bergstresser, N.J. Lowe, J.J. Voorhees, and G.D. Weinstein Psoriasis J Am Acad Dermatol 11 1984 937 947
2. E.K. Pias, J. Hilario-Vargas, N. Li, and L.A. Diaz Humoral autoimmunity in pemphigus Autoimmunity 37 2004 283 286
3. C.N. Ellis, D.C. Gorsulowsky, T.A. Hamilton, J.K. Billings, M.D. Brown, and J.T. Headington Cyclosporine improves psoriasis in a double-blind study JAMA 256 1986 3110 3116
4. H.H. Roenigk Jr., H.I. Maibach, and G.D. Weinstein Use of methotrexate in psoriasis Arch Dermatol 105 1972 363 365
5. K. Rappersberger, J.G. Meingassner, R. Fialla, D. Fodinger, B. Sterniczky, and S. Rauch Clearing of psoriasis by a novel immunosuppressive macrolide J Invest Dermatol 106 1996 701 710
6. H.S. Zackheim, R.G. Glogau, D.A. Fisher, and H.I. Maibach 6-Thioguanine treatment of psoriasis: experience in 81 patients J Am Acad Dermatol 30 1994 452 458
7. R.E. Lee, A.A. Gaspari, M.T. Lotze, A.E. Chang, and S.A. Rosenberg Interleukin 2 and psoriasis Arch Dermatol 124 1988 1811 1815
8. L.A. Asnis, and A.A. Gaspari Cutaneous reactions to recombinant cytokine therapy J Am Acad Dermatol 33 1995 393 412
9. H. Valdimarsson, B.S. Baker, I. Jonsdottir, A. Powles, and L. Fry Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today 16 1995 145 149
10. J.A. Parrish, T.B. Fitzpatrick, L. Tanenbaum, and M.A. Pathak Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light N Engl J Med 291 1974 1207 1211
11. T.R. Coven, L.H. Burack, R. Gilleaudeau, M. Keogh, M. Ozawa, and J.G. Krueger Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B Arch Dermatol 133 1997 1514 1522
12. R.S. Stern, R.B. Armstrong, T.F. Anderson, D.R. Bickers, N.J. Lowe, and L. Harber Effect of continued ultraviolet B phototherapy on the duration of remission of psoriasis: a randomized study J Am Acad Dermatol 15 1986 546 552
13. C.L. Leonardi, J.L. Powers, R.T. Matheson, B.S. Goffe, R. Zitnik, and A. Wang Etanercept as monotherapy in patients with psoriasis N Engl J Med 349 2003 2014 2022
14. U. Chaudhari, P. Romano, L.D. Mulcahy, L.T. Dooley, D.G. Baker, and A.B. Gottlieb Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial Lancet 357 2001 1842 1847
15. N. Scheinfeld Adalimumab (HUMIRA): a review J Drugs Dermatol 2 2003 375 377
16. M. Lebwohl, S.K. Tyring, T.K. Hamilton, D. Toth, S. Glazer, and N.H. Tawfik A novel targeted T-cell modulator, efalizumab, for plaque psoriasis N Engl J Med 349 2003 2004 2013
17. C.N. Ellis, and G.G. Krueger Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes N Engl J Med 345 2001 248 255
18. J.R. Abrams, M.G. Lebwohl, C.A. Guzzo, B.V. Jegasothy, M.T. Goldfarb, and B.S. Goffe CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris J Clin Invest 103 1999 1243 1252
19. A.B. Gottlieb, M. Lebwohl, S. Shirin, A. Sherr, P. Gilleaudeau, and G. Singer Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study J Am Acad Dermatol 43 2000 595 604
20. J. Bagel, W.T. Garland, D. Breneman, M. Holick, T.W. Littlejohn, and D. Crosby Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial J Am Acad Dermatol 38 1998 938 944
21. K. Ghoreschi, P. Thomas, S. Breit, M. Dugas, R. Mailhammer, and W. van Eden Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease Nat Med 9 2003 40 46
22. K. Asadullah, W.D. Docke, M. Ebeling, M. Friedrich, G. Belbe, and H. Audring Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial Arch Dermatol 135 1999 187 192
23. W.L. Trepicchio, M. Ozawa, I.B. Walters, T. Kikuchi, P. Gilleaudeau, and J.L. Bliss Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions J Clin Invest 104 1999 1527 1537
24. N. Tsankov, I. Angelova, and J. Kazandjieva Drug-induced psoriasis: recognition and management Am J Clin Dermatol 1 2000 159 165
25. R.L. Moy, T.P. Kingston, and N.J. Lowe Isotretinoin vs etretinate therapy in generalized pustular and chronic psoriasis Arch Dermatol 121 1985 1297 1301
26. M. Shbeeb, K.M. Uramoto, L.E. Gibson, W.M. O'Fallon, and S.E. Gabriel The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991 J Rheumatol 27 2000 1247 1250
27. J. Bhalerao, and A.M. Bowcock The genetics of psoriasis: a complex disorder of the skin and immune system Hum Mol Genet 7 1998 1537 1545
28. R.C. Fuhlbrigge, J.D. Kieffer, D. Armerding, and T.S. Kupper Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells Nature 389 1997 978 981
29. T. Wrone-Smith, and B.J. Nickoloff Dermal injection of immunocytes induces psoriasis J Clin Invest 98 1996 1878 1887
30. C.E. Griffiths The immunological basis of psoriasis J Eur Acad Dermatol Venereol 17 Suppl 2003 1 5
31. J.C. Prinz The role of T cells in psoriasis J Eur Acad Dermatol Venereol 17 2003 257 270
32. + T lymphocytes J Invest Dermatol 117 2001 569 575
33. U. Christen, and M.G. von Herrath Induction, acceleration or prevention of autoimmunity by molecular mimicry Mol Immunol 40 2004 1113 1120
34. B.M. Carreno, and M. Collins The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses Annu Rev Immunol 20 2002 29 53
35. M. Lebwohl, D. Sherer, K. Washenik, G.G. Krueger, A. Menter, and J. Koo A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis Int J Dermatol 41 2002 269 274
36. J.M. McGregor, J.N. Barker, E.L. Ross, and D.M. MacDonald Epidermal dendritic cells in psoriasis possess a phenotype associated with antigen presentation: in situ expression of beta 2-integrins J Am Acad Dermatol 27 1992 383 388
37. + cells in eczematous dermatitis, psoriasis, lichen planus and graft-versus-host disease Arch Dermatol Res 294 2002 297 302
38. L.M. Austin, M. Ozawa, T. Kikuchi, I.B. Walters, and J.G. Krueger The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients J Invest Dermatol 113 1999 752 759
39. D.T. Umetsu, O. Akbari, and R.H. Dekruyff Regulatory T cells control the development of allergic disease and asthma J Allergy Clin Immunol 112 2003 480 488
40. + T cells and the control of autoimmune disease Curr Opin Immunol 16 2004 695 701
41. + T cells that prevent spontaneous autoimmune encephalomyelitis J Immunol 164 2000 5499 5507
42. + regulatory T cells Nat Immunol 4 2003 330 336
43. D. Bruder, M. Probst-Kepper, A.M. Westendorf, R. Geffers, S. Beissert, and K. Loser Neuropilin-1: a surface marker of regulatory T cells Eur J Immunol 34 2004 623 630
44. + regulatory T cells in patients with multiple sclerosis J Exp Med 199 2004 971 979
45. M.R. Ehrenstein, J.G. Evans, A. Singh, S. Moore, G. Warnes, and D.A. Isenberg Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy J Exp Med 200 2004 277 285
46. + regulatory T cells in autoimmune polyglandular syndrome type II J Exp Med 199 2004 1285 1291
47. L.S. Ou, E. Goleva, C. Hall, and D.Y. Leung T regulatory cells in atopic dermatitis and subversion of their activity by superantigens J Allergy Clin Immunol 113 2004 756 763
48. C. Veldman, A. Hohne, D. Dieckmann, G. Schuler, and M. Hertl Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris J Immunol 172 2004 6468 6475
49. +CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation J Immunol 174 2005 164 173
50. Q. Tang, K.J. Henriksen, M. Bi, E.B. Finger, G. Szot, and J. Ye In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes J Exp Med 199 2004 1455 1465
51. + T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes J Exp Med 199 2004 1467 1477
52. A.M. Faria, and H.L. Weiner Oral tolerance: mechanisms and therapeutic applications Adv Immunol 73 1999 153 264
53. H.J. van der Vliet, J.W. Molling, B.M. von Blomberg, N. Nishi, W. Kolgen, and A.J. van den Eertwegh The immunoregulatory role of CD1d-restricted natural killer T cells in disease Clin Immunol 112 2004 8 23
54. A.K. Singh, M.T. Wilson, S. Hong, D. Olivares-Villagomez, C. Du, and A.K. Stanic Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis J Exp Med 194 2001 1801 1811
55. A.B. Frey, and T.D. Rao NKT cell cytokine imbalance in murine diabetes mellitus Autoimmunity 29 1999 201 214
56. L.J. Saubermann, P. Beck, Y.P. De Jong, R.S. Pitman, M.S. Ryan, and H.S. Kim Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice Gastroenterology 119 2000 119 128
57. K. Takeda, Y. Hayakawa, L. Van Kaer, H. Matsuda, H. Yagita, and K. Okumura Critical contribution of liver natural killer T cells to a murine model of hepatitis Proc Natl Acad Sci U S A 97 2000 5498 5503
58. + NK T cells associated with disease development in autoimmune-prone mice J Immunol 156 1996 4035 4040
59. R.A. Campos, M. Szczepanik, A. Itakura, M. Akahira-Azuma, S. Sidobre, and M. Kronenberg Cutaneous immunization rapidly activates liver invariant Valpha14 NKT cells stimulating B-1 B cells to initiate T cell recruitment for elicitation of contact sensitivity J Exp Med 198 2003 1785 1796
60. A.C. Chen, R.F. Lum, L.A. Criswell, and R.G. Russell Men with early rheumatoid arthritis are more likely to respond to treatment with etanercept than women; older women are more likely to respond to methotrexate than older men Arthritis Rheum 48 Suppl 2003 S130
61. A.L. Cameron, B. Kirby, and C.E. Griffiths Circulating natural killer cells in psoriasis Br J Dermatol 149 2003 160 164
62. B. Bonish, D. Jullien, Y. Dutronc, B.B. Huang, R. Modlin, and F.M. Spada Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells J Immunol 165 2000 4076 4085
63. E. Lee, W.L. Trepicchio, J.L. Oestreicher, D. Pittman, F. Wang, and F. Chamian Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris J Exp Med 199 2004 125 130
64. C.L. Kauffman, N. Aria, E. Toichi, T.S. McCormick, K.D. Cooper, and A.B. Gottlieb A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis J Invest Dermatol 123 2004 1037 1044
65. B. Beutler, and A. Cerami Tumor necrosis, cachexia, shock, and inflammation: a common mediator Annu Rev Biochem 57 1988 505 518
66. P. Vassalli The pathophysiology of tumor necrosis factors Annu Rev Immunol 10 1992 411 452
67. I. Kimber, M. Cumberbatch, R.J. Dearman, M. Bhushan, and C.E. Griffiths Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization Br J Dermatol 142 2000 401 412
68. M.L. Moss, S.L. Jin, J.D. Becherer, D.M. Bickett, W. Burkhart, and W.J. Chen Structural features and biochemical properties of TNF-alpha converting enzyme (TACE) J Neuroimmunol 72 1997 127 129
69. P.J. Barnes, and M. Karin Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases N Engl J Med 336 1997 1066 1071
70. B.J. Nickoloff, G.D. Karabin, J.N. Barker, C.E. Griffiths, V. Sarma, and R.S. Mitra Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis Am J Pathol 138 1991 129 140
71. P. Ettehadi, M.W. Greaves, D. Wallach, D. Aderka, and R.D. Camp Elevated tumor necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions Clin Exp Immunol 96 1994 146 151
72. G. Partsch, G. Steiner, B.F. Leeb, A. Dunky, H. Broll, and J.S. Smolen Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid J Rheumatol 24 1997 518 523
73. C. Ritchlin, S.A. Haas-Smith, D. Hicks, J. Cappuccio, C.K. Osterland, and R.J. Looney Patterns of cytokine production in psoriatic synovium J Rheumatol 25 1998 1544 1552
74. C.L. Danning, G.G. Illei, C. Hitchon, M.R. Greer, D.T. Boumpas, and I.B. McInnes Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis Arthritis Rheum 43 2000 1244 1256
75. J. Banchereau, V. Pascual, and A.K. Palucka Autoimmunity through cytokine-induced dendritic cell activation Immunity 20 2004 539 550
76. R. Ruckert, K. Asadullah, M. Seifert, V.M. Budagian, R. Arnold, and C. Trombotto Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis? J Immunol 165 2000 2240 2250
77. J.G. Krueger The immunologic basis for the treatment of psoriasis with new biologic agents J Am Acad Dermatol 46 2002 1 23
78. B.J. Nickoloff, and F.O. Nestle Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities J Clin Invest 113 2004 1664 1675
79. A. Gilhar, Y. Ullmann, H. Kerner, B. Assy, R. Shalaginov, and S. Serafimovich Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes: induction of psoriasis by cells with natural killer receptors J Invest Dermatol 119 2002 384 391
80. B.J. Nickoloff, B. Bonish, B.B. Huang, and S.A. Porcelli Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system J Dermatol Sci 24 2000 212 225
81. O. Boyman, H.P. Hefti, C. Conrad, B.J. Nickoloff, M. Suter, and F.O. Nestle Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-{alpha} J Exp Med 199 2004 731 736
82. J. Cheng, K. Turksen, Q.C. Yu, H. Schreiber, M. Teng, and E. Fuchs Cachexia and graft-vs.-host-disease-type skin changes in keratin promoter-driven TNF alpha transgenic mice Genes Dev 6 1992 1444 1456
83. J.M. Carroll, T. Crompton, J.P. Seery, and F.M. Watt Transgenic mice expressing IFN-gamma in the epidermis have eczema, hair hypopigmentation, and hair loss J Invest Dermatol 108 1997 412 422
84. R. Burns, I. Luzina, A. Nasir, C.G. Haidaris, R.K. Barth, and A.A. Gaspari Keratinocyte-derived, CD80-mediated costimulation is associated with hapten-specific IgE production during contact hypersensitivity to TH1 haptens J Allergy Clin Immunol 115 2005 383 390
85. B.J. Nickoloff, R.S. Mitra, K. Lee, L.A. Turka, J. Green, and C. Thompson Discordant expression of CD28 ligands, BB-1, and B7 on keratinocytes in vitro and psoriatic cells in vivo Am J Pathol 142 1993 1029 1040
86. R. Kunstfeld, S. Hirakawa, Y.K. Hong, V. Schacht, B. Lange-Asschenfeldt, and P. Velasco Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia Blood 104 2004 1048 1057
87. D.M. Underhill Toll-like receptors and microbes take aim at each other Curr Opin Immunol 16 2004 483 487
88. B.S. Baker, J.M. Ovigne, A.V. Powles, S. Corcoran, and L. Fry Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis Br J Dermatol 148 2003 670 679
89. N.H. Litjens, M. Rademaker, B. Ravensbergen, D. Rea, M.J. van der Plas, and B. Thio Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses Eur J Immunol 34 2004 565 575
90. B. Vega, C. Ferret, A. Jomard, and S. Michel Regulation of toll-like receptor-2 expression by adapalene: implications for the treatment of inflammatory acne J Invest Dermatol 121 2003 156
91. J.L. Curry, J.Z. Qin, B. Bonish, R. Carrick, P. Bacon, and J. Panella Innate immune-related receptors in normal and psoriatic skin Arch Pathol Lab Med 127 2003 178 186
92. Y. Okamura, M. Watari, E.S. Jerud, D.W. Young, S.T. Ishizaka, and J. Rose The extra domain A of fibronectin activates Toll-like receptor 4 J Biol Chem 276 2001 10229 10233
93. K.M. Ting, D. Rothaupt, T.S. McCormick, C. Hammerberg, G. Chen, and A.C. Gilliam Overexpression of the oncofetal Fn variant containing the EDA splice-in segment in the dermal-epidermal junction of psoriatic uninvolved skin J Invest Dermatol 114 2000 706 711
94. M. Gilliet, C. Conrad, M. Geiges, A. Cozzio, W. Thurlimann, and G. Burg Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors Arch Dermatol 140 2004 1490 1495
95. F. Heil, H. Hemmi, H. Hochrein, F. Ampenberger, C. Kirschning, and S. Akira Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8 Science 303 2004 1526 1529
96. S.S. Diebold, T. Kaisho, H. Hemmi, S. Akira, and C. Reis e Sousa Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA Science 303 2004 1529 1531